In vitro and in vivo anticancer activity of copper bis(thiosemicarbazone) complexes

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 722-734

  Palanimuthu, Duraippandi ^a   Shinde, Sridevi Vijay ^a   Somasundaram, Kumaravel ^a   Samuelson, Ashoka G ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COPPER BENZYL BIS(4 PYRROLIDINYL 3 THIOSEMICARBAZONE); COPPER BENZYL BIS(4 PYRROLIDINYL 3 THIOSEMICARBAZONE) PERCHLORATE; COPPER BIACETYL BIS(4 PYRROLIDINYL 3 THIOSEMICARBAZONE); COPPER BIACETYL BIS(4 PYRROLIDINYL 3 THIOSEMICARBAZONE) PERCHLORATE; COPPER BIS(THIOSEMICARBAZONE) COMPLEX; COPPER COMPLEX; COPPER GLYOXAL BIS(4 METHYL 4 PHENYL 3 THIOSEMICARBAZONE); COPPER GLYOXAL BIS(4 METHYL 4 PHENYL 3 THIOSEMICARBAZONE) CHLORIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DOXORUBICIN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; ZINC COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HCT116; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIC POTENTIOMETRY; CYTOPATHOGENIC EFFECT; DNA CLEAVAGE; DNA SYNTHESIS INHIBITION; DRUG DNA BINDING; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT; ULTRAVIOLET SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; MICE; MODELS, MOLECULAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THIOSEMICARBAZONES;

EID: 84873925036     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300938r     Document Type: Article

References (71)

1. Jung, Y.; Lippard, S. J. Direct cellular responses to platinum-induced DNA damage Chem. Rev. 2007, 107, 1387-1407
2. Rabik, C. A.; Dolan, M. E. Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat. Rev. 2007, 33, 9-23
3. Zhang, C. X.; Lippard, S. J. New metal complexes as potential therapeutics Curr. Opin. Chem. Biol. 2003, 7, 481-489
4. van Rijt, S. H. V.; Sadler, P. J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs of anticancer drugs Drug Discovery Today 2009, 14, 1089-1097
5. Gasser, G.; Ott, I.; Metzler-Nolte, N. Organometallic anticancer compounds J. Med. Chem. 2011, 54, 3-25
6. Sanghamitra, N. J.; Phatak, P.; Das, S.; Samuelson, A. G.; Somasundaram, K. Mechanism of cytotoxicity of copper(I) complexes of 1,2- bis(diphenylphosphino)ethane J. Med. Chem. 2005, 48, 977-985
7. Seelig, M. H.; Berger, M. R.; Keppler, B. K. Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats J. Cancer Res. Clin. Oncol. 1992, 118, 195-200
8. Dyson, P. J.; Sava, G. Metal-based antitumour drugs in the post genomic era Dalton Trans. 2006, 1929-1933
9. Zhong, X.; Yi, J.; Sun, J.; Wei, H. L.; Liu, W. S.; Yu, K. B. Synthesis and crystal structure of some transition metal complexes with a novel bis-Schiff base ligand and their antitumor activities Eur. J. Med. Chem. 2006, 41, 1090-1092
10. Matesanz, A. I.; Perez, J. M.; Navarro, P.; Moreno, J. M.; Colacio, E.; Souza, P. Synthesis and characterization of novel palladium (II) complexes of bis(thiosemicarbazone). Structure, cytotoxic activity and DNA binding of Pd(II)-benzyl bis(thiosemicarbazonate) J. Inorg. Biochem. 1999, 76, 29-37
11. Van Giessen, G. J.; Petering, H. G. Metal complexes of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone) and related ligands as antitumor agents J. Med. Chem. 1968, 11, 695-699
12. Pascu, S. I.; Waghorn, P. A.; Conry, T. D.; Lin, B.; Betts, H. M.; Dilworth, J. R.; Sim, R. B.; Churchill, G. C.; Aigbirhio, F. I.; Warren, J. E. Cellular confocal fluorescence studies and cytotoxic activity of new Zn(II) bis(thiosemicarbazonato) complexes Dalton Trans. 2008, 16, 2107-2110
13. 4-azacyclicthiosemicarbazones) J. Inorg. Biochem. 1988, 34, 41-54
14. Murthy, N.; Dharmarajan, T. S. Synthesis, characterization and biological activity of copper(II) complexes with phenylglyoxal bis(thiosemicarbazones) Asian J. Chem. 2002, 14, 1325-1330
15. Price, A.; Caragounis, A.; Paterson, B. M.; Filiz, G.; Volitakis, I.; Masters, C. L.; Barnham, K. J.; Donnelly, P. S.; Crouch, P. J.; White, A. R. Sustained activation of glial cell epidermal growth factor receptor by bis(thiosemicarbazonato) metal complexes is associated with inhibition of protein tyrosine phosphatase activity J. Med. Chem. 2009, 52, 6606-6620
16. Xiao, Z.; Donnelly, P. S.; Zimmermann, M.; Wedd, A. G. Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. Insights into mechanisms of copper uptake and hypoxia selectivity Inorg. Chem. 2008, 47, 4338-4347
17. John, E. K.; Green, M. A. Structure-activity relationships for metal-labeled blood flow tracers: comparison of keto aldehyde bis(thiosemicarbazonato)copper(II) derivatives J. Med. Chem. 1990, 33, 1764-1770
18. Booth, B. A.; Sartorelli, A. C. Synergistic interaction of kethoxal bis (thiosemicarbazone) and cupric ions in sarcoma 180 Nature 1966, 210, 104-105
19. Pascu, S. I.; Waghorn, P. A.; Kennedy, B. W. C.; Arrowsmith, R. L.; Bayly, S. R.; Dilworth, J. R.; Christlieb, M.; Tyrrell, R. M.; Zhong, J.; Kowalczyk, R. M.; Collison, D.; Aley, P. K.; Churchill, G. C.; Aigbirhio, F. I. Fluorescent copper(II) bis(thiosemicarbazonates): synthesis, structures, electron paramagnetic resonance, radiolabeling, in vitro cytotoxicity and confocal fluorescence microscopy studies Chem. Asian J. 2010, 5, 506-519
20. Dilanyan, E. R.; Ovsepyan, T. R.; Arsenyan, F. G.; Stepanyan, G. M.; Garibdzhanyan, B. T. Antitumor activity of substituted methylglyoxalbisthiosemicarbazones and their copper(II) chelates Pharm. Chem. J. 2008, 42, 504-506
21. Kowol, C. R.; Heffeter, P.; Miklos, W.; Gille, L.; Trondl, R.; Cappellacci, L.; Berger, W.; Keppler, B. K. Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds J. Biol. Inorg. Chem. 2012, 17, 409-423
22. Lovejoy, D. B.; Jansson, P. J.; Brunk, U. T.; Wong, J.; Ponka, P.; Richardson, D. R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes Cancer Res. 2011, 71, 5871-5880
23. Jansson, P. J.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: Identification of pronounced redox activity and characterization of their antitumor activity J. Med. Chem. 2010, 53, 5759-5769
24. Hall, I. H.; Lackey, C. B.; Kistler, T. Y.; Ives, J. S.; Beraldo, H.; Ackerman, L. J.; West, D. X. The cytotoxicity of symmetrical and unsymmerical bis(thiosemicarbazone) and their metal complexes in murine and human tumor cells Arch. Pharm. Pharm. Med. Chem. 2000, 333, 217-225
25. Paterson, B. M.; Donnelly, P. S. Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals Chem. Soc. Rev. 2011, 40, 3005-3018
26. Dearling, J. L. J.; Packard, A. B Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM Nucl. Med. Biol. 2010, 37, 237-243
27. Holland, J. P.; Barnard, P. J.; Collison, D.; Dilworth, J. R.; Edge, R.; Green, J. C.; McInnes, E. J. L. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals Chem.-Eur. J. 2008, 14, 5890-5907
28. Dearling, J. L. J.; Lewis, J. S.; Mullen, G. E. D.; Welch, M. J.; Blower, P. J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships J. Biol. Inorg. Chem. 2002, 7, 249-259
29. Dearling, J. L. J.; Lewis, J. S.; McCarthy, D. W.; Welch, M. J.; Blower, P. J. Redox-active metal complexes for imaging hypoxic tissues: structure-activity relationships in copper (II) bis(thiosemicarbazone) complexes Chem. Commun. 1998, 2531-2532
30. 4- methylthiosemicarbazone): an agent for radiotherapy Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 1206-1211
31. Vavere, A. L.; Lewis, J. S. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia Dalton Trans. 2007, 4893-4902
32. 64Cu-ATSM PET/CT in Cervical Cancer. In ClinicalTrials.gov, Bethesda, MD (cited March 28, 2012). Available from http://clinicaltrials.gov/ct2/show/NCT00004451. NLM Identifier: NCT00004451.
33. 64Cu- complexes for the positron emission tomography imaging of hypoxia J. Med. Chem. 2011, 51, 2985-2991
34. II Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 47-52
35. Fujibayashi, Y.; Taniuchi, H.; Yonekura, Y.; Ohtani, H.; Konishi, J.; Yokoyama, A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential J. Nucl. Med. 1997, 38, 1155-1160
36. 4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 3030-3035
37. Green, M. A.; Klippenstein, D. L.; Tennison, J. R. Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET J. Nucl. Med. 1988, 29, 1549-1557
38. Dayal, D.; Palanimuthu, D.; Shinde, S. V.; Somasundaram, K.; Samuelson, A. G. A novel zinc bis(thiosemicarbazone) complex for live cell imaging J. Biol. Inorg. Chem. 2011, 16, 621-632
39. 4] derived from 2-acetylpyridine-N(4), N(4)-(butane-1,4-diyl) thiosemicarbazone (HPranthas) J. Mol. Struct. 2005, 737, 61-67
40. Christlieb, M.; Dilworth, J. R. Ligands for molecular imaging: The synthesis of bis(thiosemicarbazone) ligands Chem.-Eur. J. 2006, 12, 6194-6206
41. Beraldo, H.; Boyd, L. P.; West, D. X. Copper(II) and nickel(II) complexes of glyoxaldehyde bis{N(3)-substituted thiosemicarbazones} Transition Met. Chem. 1998, 23, 67-71
42. Alsop, L.; Cowley, A. R.; Dilworth, J. R.; Donnelly, P. S.; Peach, J. M.; Rider, J. T. Investigations into some aryl substituted bis(thiosemicarbazones) and their copper complexes Inorg. Chim. Acta 2005, 358, 2770-2780
43. Blower, P. J.; Castle, T. C.; Cowley, A. R.; Dilworth, J. R.; Donnelly, P. S.; Labisbal, E.; Sowrey, F. E.; Teat, S. J.; Went, M. J. Structural trends in copper(II) bis(thiosemicarbazone) radiopharmaceuticals Dalton Trans. 2003, 4416-4425
44. Cowley, A. R.; Davis, J.; Dilworth, J. R.; Donnelly, P. S.; Dobson, R.; Nightingale, A.; Peach, J. M.; Shore, B.; Kerr, D.; Seymour, L. Fluorescence studies of the intra-cellular distribution of zinc bis(thiosemicarbazone) complexes in human cancer cells Chem. Commun. 2005, 845-847
45. Skehn, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMohan, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 1990, 82, 1107-1112
46. Price, K. A.; Crouch, P. J.; Volitakis, I.; Paterson, B. M.; Lim, S.; Donnelly, P. S.; White, A. R. Mechanisms controlling the cellular accumulation of copper bis(thiosemicarbazonato) complexes Inorg. Chem. 2011, 50, 9594-9605
47. Gopal, Y. N. V; Jayaraju, D.; Kondapi, A. K. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: A ligand-dependent mode of action Biochemistry 1999, 38, 4382-4388
48. Bhuyan, B. K.; Betz, T. Studies on the mode of action of the copper(II) chelate of 2-keto-3-ethoxybutyraldehyde-bis(thiosemicarbazone) Cancer Res. 1968, 28, 758-763
49. Vock, C. A.; Ang, W. H.; Scolaro, C.; Phillips, A. D.; Lagopoulos, L.; Juillerat-Jeanneret, L.; Sava, G.; Scopelliti, R.; Dyson, P. J. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms J. Med. Chem. 2007, 50, 2166-2175
50. Karki, S. S.; Panjamurthy, K.; Kumar, S.; Nambiar, N.; Ramareddy, S. A.; Chiruvella, K. K.; Raghavan, S. C. Synthesis and Biological Evolution of novel 2-aralkyl-5-substituted-6-(4′-fluorophenyl)-imidazo[2,1-b][1,3,4] thiadiazole derivatives as potent anticancer agents Eur. J. Med. Chem. 2011, 46, 2109-2116
51. Miller, M. C., III; Stineman, C. N.; Vance, J. R.; West, D. X.; Hall, I. H. The cytotoxicity of copper(II) complexes of 2-acetyl-pyridyl-4-Nsubstituted thiosemicarbazones Anticancer Res. 1998, 18 (6A) 4131-4139
52. Miller, M. C., III; Stineman, C. N.; Vance, J. R.; West, D. X.; Hall, I. H. Multiple mechanisms for cytotoxicity induced by copper(II) complexes of 2-acetylpyrazine-N-substituted thiosemicarbazones Appl. Organomet. Chem. 1999, 13, 9-19
53. 4-substituted thiosemicarbazones and their Cu(II) complexes J. Med. Chem. 2011, 54, 2391-2398
54. Tewey, K. M.; Rowe, T. C.; Yang, L.; Halligan, B. D.; Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 1984, 226, 466-468
55. Gopal, Y. N. V.; Kondapi, A. K. Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium J. Biosci. 2001, 26, 271-276
56. Roskams, J.; Rodgers, L. Lab Ref: A handbook of recipes, reagents, and other reference tools for use at the bench; I. K. International Pvt. Ltd.: New Delhi, 2002.
57. Farrugia, L. J. WinGX suite for single crystal small molecule crystallography J. Appl. Crystallogr. 1999, 32, 837-838
58. Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A. Completion and refinement of crystal structures with SIR 92 J. Appl. Crystallogr. 1993, 26, 343-350
59. Sheldrick, G. M. SHELXL-97. A program for the refinement of crystal structures, University of Goettingen, 1997.
60. Sun, T.; Pan, Y. L.; Wu, J. Y.; Zhou, H. P.; Zhao, Z. Z.; Tian, Y. P. Synthesis, luminescence and cyclic voltammetric studies of several novel carboxylato diruthenium complexes Transition Met. Chem. 2007, 32, 449-455
61. Fujita, T.; Iwasa, J.; Hansch, C. A new substituent constant, π, derived from partition coefficients J. Am. Chem. Soc. 1964, 86, 5175-5180
62. Hansch, C.; Maloney, P. P.; Fujita, T.; Muir, R. Correlation of biological activity of phenoxyacetic acids with hammett substituent constants and partition coefficients Nature 1962, 194, 178-180
63. Wajapeyee, N.; Britto, R.; Ravishankar, H. M.; Somasundaram, K. Apoptosis induction by activator protein 2α involves transcriptional repression of Bcl-2 J. Biol. Chem. 2006, 281, 16207-16219
64. Schreiber, E.; Matthias, P.; Muller, M. M.; Schaffner, W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells Nucleic Acids Res. 1989, 17, 6419
65. Das, S.; El-Deiry, W. S.; Somasundaram, K. Regulation of p53 homologues p73 by adenovirus oncogene E1A J. Biol. Chem. 2003, 278, 1831-18320
66. Mukhopadhyay, D.; SundarRaj, S.; Alok, A.; Karande, A. J. Glycodelin A, not glycodelin S, is apoptotically active J. Biol. Chem. 2004, 279, 8577-8584
67. Das, S.; El-Deiry, W. S.; Somasundaram, K. Efficient growth inhibition of HPV 16 E16 expressing cancer cells by adenovirus expressing p53 homologue p73β Oncogene 2003, 22, 8394-8402
68. Reichman, M. E.; Rice, S. A.; Thomas, C. A.; Doty, P. A further examination of the molecular weight and size of desoxypentose nucleic acid J. Am. Chem. Soc. 1954, 76, 3047-3053
69. Cohen, G.; Eisenberg, H. Viscosity and sedimentation study of sonicated DNA-proflavine complexes Biopolymers 1969, 8, 45-55
70. Satyanarayana, S.; Dabrowiak, J. C.; Chaires, J. B. Neither Δ-nor Λ-tris(phenanthroline) ruthenium(II) binds to DNA by classical intercalation Biochemistry 1992, 31, 9319-9324
71. Das, S.; Somasundaram, K. Therapeutic potential of an adenovirus expressing p73 beta, a p53 homologue, against human papilloma virus positive cervical cancer in vitro and in vivo Cancer Biol. Ther. 2006, 5, 210-217